Several molecular therapies targeting human epidermal growth factor receptor 2 (HER2) and cyclin-dependent kinases 4 and 6 (CDK4/6) have improved the efficacy of breast cancer treatment and the breast cancer survival rate [172,173]. Here, ERBB2 is linked to breast carcinoma.